HIGHLIGHTS OF PRESCRIBING INFORMATION

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Aktív összetevők:

OLANZAPINE (UNII: N7U69T4SZR) (OLANZAPINE - UNII:N7U69T4SZR)

Beszerezhető a:

AvPAK

INN (nemzetközi neve):

OLANZAPINE

Összetétel:

OLANZAPINE 2.5 mg

Az alkalmazás módja:

ORAL

Recept típusa:

PRESCRIPTION DRUG

Terápiás javallatok:

Olanzapine tablets, USP are indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see Clinical Studies ( 14.1)] . When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions ( 5.4)]. Monotherapy — Olanzapine Tablets, USP are indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I

Termék összefoglaló:

Olanzapine Tablets, USP 2.5 mg are white, round, biconvex film-coated tablets, engraved “APO” on one side, “OLA” over “2.5” on the other side. They are supplied as follows: NDC 50268-609-15  (10 tablets per card, 5 cards per carton). Olanzapine Tablets, USP 5 mg are white, round, biconvex film-coated tablets, engraved “APO” on one side, “OLA” over “5” on the other side. They are supplied as follows: NDC 50268-610-15  (10 tablets per card, 5 cards per carton). Olanzapine Tablets, USP 7.5 mg are white, round, biconvex film-coated tablets, engraved “APO” on one side, “OLA” over “7.5” on the other side. They are supplied as follows: NDC 50268-611-15  (5 tablets per card, 10 cards per carton). Olanzapine Tablets, USP 10 mg are white, round, biconvex film-coated tablets, engraved “APO” on one side, “OLA” over “10” on the other side. They are supplied as follows: NDC 50268-612-13  (5 tablets per card, 6 cards per carton). Olanzapine Tablets, USP 15 mg are light blue, elliptical, biconvex film-coated tablets, engraved “APO” on one side, “OLA 15” on the other side. They are supplied as follows: NDC 50268-613-15  (10 tablets per card, 5 cards per carton). Olanzapine Tablets, USP 20 mg are light pink, elliptical, biconvex film-coated tablets, engraved “APO” on one side, “OLA 20” on the other side. They are supplied as follows: NDC 50268-614-15  (10 tablets per card, 5 cards per carton). Store olanzapine tablets at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect olanzapine tablets from light and moisture.

Engedélyezési státusz:

Abbreviated New Drug Application

Betegtájékoztató

AvPAK
----------
Medication Guide
Olanzapine Tablets, USP
(oh lan′ za peen)
Read the Medication Guide that comes with olanzapine tablets before
you start taking it and each time you
get a refill. There may be new information. This Medication Guide does
not take the place of talking to your
doctor about your medical condition or treatment. Talk with your
doctor or pharmacist if there is something
you do not understand or you want to learn more about olanzapine
tablets.
What is the most important information I should know about olanzapine
tablets?
Olanzapine tablets may cause serious side effects, including:
1.
Increased risk of death in elderly people who are confused, have
memory loss and have lost touch
with reality (dementia-related psychosis).
2.
High blood sugar (hyperglycemia).
3.
High fat levels in your blood (increased cholesterol and
triglycerides), especially in teenagers age 13
to 17 or when used in combination with fluoxetine in children age 10
to 17.
4.
Weight gain, especially in teenagers age 13 to 17 or when used in
combination with fluoxetine in
children age 10 to 17.
These serious side effects are described below.
1.
Increased risk of death in elderly people who are confused, have
memory loss and have lost touch
with reality (dementia-related psychosis). Olanzapine tablets are not
approved for treating psychosis
in elderly people with dementia.
2.
High blood sugar (hyperglycemia). High blood sugar can happen if you
have diabetes already or if
you have never had diabetes. High blood sugar could lead to:
•
a build up of acid in your blood due to ketones (ketoacidosis)
•
coma
•
death
Your doctor should do tests to check your blood sugar before you start
taking olanzapine tablets and
during treatment. In people who do not have diabetes, sometimes high
blood sugar goes away when
olanzapine tablets are stopped. People with diabetes and some people
who did not have diabetes
before taking olanzapine tablets need to take medicine for high blood
sugar even after they stop
taking olanzapine tablets.

Termékjellemzők

OLANZAPINE- OLANZAPINE TABLET, FILM COATED
AVPAK
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
OLANZAPINE TABLETS, USP
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
OLANZAPINE TABLETS, USP SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OLANZAPINE TABLETS,
USP.
OLANZAPINE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1996
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED
PSYCHOSIS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH
ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED
RISK OF DEATH. OLANZAPINE TABLETS ARE NOT APPROVED FOR THE TREATMENT
OF PATIENTS WITH DEMENTIA-RELATED
PSYCHOSIS. ( 5.1, 5.12, 17.2)
WHEN USING OLANZAPINE TABLETS AND FLUOXETINE IN COMBINATION, ALSO
REFER TO THE BOXED WARNING SECTION
OF THE PACKAGE INSERT FOR SYMBYAX
.
RECENT MAJOR CHANGES
Warnings and Precautions:
Metabolic Changes (5.4) 12/2014
Orthostatic Hypotension (5.6) 07/2015
Hyperprolactinemia (5.13) 12/2014
INDICATIONS AND USAGE
Olanzapine tablets, USP are an atypical antipsychotic indicated:
_As oral formulation for the:_
Treatment of schizophrenia. ( 1.1)
Adults: Efficacy was established in three clinical trials in patients
with schizophrenia: two 6-week trials and one
maintenance trial. ( 14.1)
Adolescents (ages 13 to 17): Efficacy was established in one 6- week
trial in patients with schizophrenia ( 14.1). The
increased potential (in adolescents compared with adults) for weight
gain and dyslipidemia may lead clinicians to
consider prescribing other drugs first in adolescents. ( 1.1)
Acute treatment of manic or mixed episodes associated with bipolar I
disorder and maintenance treatment of bipolar I
disorder. ( 1.2)
Adults: Efficacy was established in three clinical trials in patients
with manic or mixed episodes of bipolar I disorder:
two 3- to 4-week trials and one maintenance trial. ( 14.2)
Adolescents (ages 13 to 17): Efficacy was established in one 3- week
trial in patients with manic or mixed episodes